University of Oulu

Kaipainen, Aku et al. ‘Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study’. 1 Jan. 2020 : 751 – 765. https://doi.org/10.3233/JAD-200175

Cerebrospinal fluid and MRI biomarkers in neurodegenerative diseases : a retrospective memory clinic-based study

Saved in:
Author: Kaipainen, Aku1; Jääskeläinen, Olli1; Liu, Yawu1,2;
Organizations: 1University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland
2Department of Radiology, Kuopio University Hospital, Kuopio, Finland
3Department of Neurology, Kuopio University Hospital, Kuopio, Finland
4Research Unit of Clinical Neuroscience, Neurology, University of Oulu, Oulu, Finland
5MRC, Oulu University Hospital, Oulu, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.7 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2020070646942
Language: English
Published: IOS Press, 2020
Publish Date: 2020-07-06
Description:

Abstract

Background: Cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) biomarkers of neurodegenerative diseases are relatively sensitive and specific in highly curated research cohorts, but proper validation for clinical use is mostly missing.

Objective: We studied these biomarkers in a novel memory clinic cohort with a variety of different neurodegenerative diseases.

Methods: This study consisted of 191 patients with subjective or objective cognitive impairment who underwent neurological, CSF biomarker (Aβ42, p-tau, and tau) and T1-weighted MRI examinations at Kuopio University Hospital. We assessed CSF and imaging biomarkers, including structural MRI focused on volumetric and cortical thickness analyses, across groups stratified based on different clinical diagnoses, including Alzheimer’s disease (AD), frontotemporal dementia, dementia with Lewy bodies, Parkinson’s disease, vascular dementia, and mild cognitive impairment (MCI), and subjects with no evidence of neurodegenerative disease underlying the cognitive symptoms. Imaging biomarkers were also studied by profiling subjects according to the novel amyloid, tau, and, neurodegeneration (AT(N)) classification.

Results: Numerous imaging variables differed by clinical diagnosis, including hippocampal, amygdalar and inferior lateral ventricular volumes and entorhinal, lingual, inferior parietal and isthmus cingulate cortical thicknesses, at a false discovery rate (FDR)-corrected threshold for significance (analysis of covariance; p < 0.005). In volumetric comparisons by AT(N) profile, hippocampal volume significantly differed (p < 0.001) between patients with normal AD biomarkers and patients with amyloid pathology.

Conclusion: Our analysis suggests that CSF and MRI biomarkers function well also in clinical practice across multiple clinical diagnostic groups in addition to AD, MCI, and cognitively normal groups.

see all

Series: Journal of Alzheimer's disease
ISSN: 1387-2877
ISSN-E: 1875-8908
ISSN-L: 1387-2877
Volume: 75
Issue: 3
Pages: 751 - 765
DOI: 10.3233/JAD-200175
OADOI: https://oadoi.org/10.3233/JAD-200175
Type of Publication: A1 Journal article – refereed
Field of Science: 3112 Neurosciences
3124 Neurology and psychiatry
3126 Surgery, anesthesiology, intensive care, radiology
Subjects:
Funding: This study was funded by The Finnish Medical Foundation, Finnish Cultural Foundation, North Savo Regional fund, Orion Research Foundation, Maire Taponen Foundation and Finnish Brain Foundation sr.
Copyright information: © 2020 – IOS Press and the authors. All rights reserved. This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
  https://creativecommons.org/licenses/by-nc/4.0/